(Q40346338)

19 September 2017

title

Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies (English)

1 reference

19 September 2017

Davies MA

1

1 reference

19 September 2017

Setola V

2

1 reference

19 September 2017

Strachan RT

3

1 reference

19 September 2017

Sheffler DJ

4

1 reference

19 September 2017

Salay E

5

1 reference

19 September 2017

Hufeisen SJ

6

1 reference

19 September 2017

Roth BL

7

1 reference

19 September 2017

publication date

1 January 2006

1 reference

The Pharmacogenomics Journal

19 September 2017

published in

1 reference

19 September 2017

volume

6

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

42-51

1 reference

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Pharmacogenetics of psychotropic drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Back to where it all started: monoamines and behavior--from drug responses to genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Serotonin and Hallucinogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Pharmacogenetics of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Vulnerability to psychosis associated with hallucinogen use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Analysis of competitive agonist-antagonist interactions by nonlinear regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Genetic variation of the 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

7 January 2021

5HT 2a receptor T102C polymorphism and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

7 January 2021

Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

7 January 2021

The assessment of antagonist potency under conditions of transient response kinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500342

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500342

1 reference

19 September 2017

1 reference